Part of the Stock Digest group of websites: Visit Small Cap Stock Digest  

Cardiol Therapeutics Introducing Major Supply of Pharmaceutical CBD to Meet Supply Crunch -- CFN Media

Seattle, Washington--(Newsfile Corp. - January 30, 2019) - CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Cardiol Therapeutics' (TSX: CRDL) upcoming launch of its pharmaceutical CBD products, with the capacity to scale manufacturing to metric tonnes per year.



Cannot view this video? Visit:
https://www.youtube.com/watch?v=Ya0nHPZ5Obs

In Canada, registered medical patients have been able to access cannabis-derived cannabidiol (CBD) oils since 2001, and the government's move to legalize cannabis in October 2018 opened the adult-use market. According to an article by CBC, the result has been a shortage of medicinal CBD, though opinions vary on exact reasons for the current lack of supply. According to James O'Hara, of the advocacy group Canadians for Fair Access to Medical Marijuana, "It's actually more than a supply issue. Really, it's something of a health crisis now. Unfortunately, there are no regulations in place to actually guarantee supply for the medical market."

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/5503/42549_4f2c7d65d4b54bb1_001full.jpg

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/5503/42549_4f2c7d65d4b54bb1_001full.jpg

Source: New Frontier Data

The Canadian medical market is only expected to grow, with forecasts calling for more than $2 billion of spending by the end of 2020.

On the pharmaceutical front, as science catches up after years of prohibition, research indicates CBD may have a wide array of health benefits. Companies across the globe are advancing drug candidates to address conditions ranging from seizures to inflammation to cancer. The opportunity is tremendous. For example, Epidiolex, the only FDA-approved CBD drug, to treat a small family of rare illnesses, is estimated to generate $625 million in international annual revenue by 2022.

The questions underlying these trends are: Where will all the CBD come from? And more to the point, where will the pure pharmaceutical CBD, manufactured in Health Canada and FDA approved facilities that meet the strictest regulations, come from? Cardiol Therapeutics (TSX: CRDL) is providing these answers.

Partnerships Drive Capability

In 2017, Cardiol secured an exclusive agreement with Dalton Pharma Services, which at the time was the one of the very few Health Canada approved and FDA registered companies in Canada licensed to produce pharmaceutical CBD. The program was initially conceived so Cardiol could secure the supply needed to conduct its clinical trial program, with the two companies working together on the formulations required. Following the deal, Dalton's founder, Peter Pekos, took a seat on Cardiol's Board of Directors.

Since that initial agreement, the opportunity to manufacture and sell pharmaceutical CBD around the world became clear. Cardiol now has an exclusive global manufacturing agreement with Dalton for the supply of pharmaceutical CBD for commercial introduction.

To further boost capacity, Cardiol has engaged in an exclusive supply agreement with Noramco, a global leader in the development and manufacture of active pharmaceutical ingredients. This agreement covers the Canadian and Mexican markets and gives Cardiol a path to significantly scale its production to metric tonnes of CBD per year.

Canada's only GMP Manufactured, Pure THC-Free CBD

By partnering with Dalton and Noramco, Cardiol is assured of the highest quality product manufactured in the most advanced and regulated facilities.

Pharmaceutical CBD can provide the material for drug research like Cardiol's existing program. It can be sold on its own to medical patients in legal jurisdictions. It can also be the primary ingredient in any number of CBD products, ranging from edibles to creams, nutraceuticals to pharmaceuticals.

Looking Ahead

Cardiol Therapeutics plans on introducing its pharmaceutical CBD line in H2 2019. The company views this as a significant revenue opportunity that will financially support its clinical research. The clinical trial process is long and fraught with pitfalls, but the rewards are vast in terms of revenue potential. In the meantime, Cardiol Therapeutics is distinguishing itself from other researchers by providing a significant but related revenue stream. Stay tuned.

Please follow the link to read the full article and see the interview: https://www.cannabisfn.com/cardiol-therapeutics-introducing-major-supply-of-pharmaceutical-cbd-to-meet-supply-crunch/

About CFN Media

For Visitors and Viewers

CFN Media's Cannabis Financial Network (CannabisFN.com) is the destination for savvy investors and business people profiting from the worldwide cannabis industry. Viewers will see breaking news, exclusive content and original programming involving the people, companies and investments shaping the industry.

For Cannabis Businesses & Companies

CFN Media is a leading agency and financial media network dedicated to the cannabis industry. We help private, pre-public and public cannabis companies in the US and Canada attract capital, investors and media attention.

Our powerful digital media and distribution platform conveys a company's message and value proposition directly to accredited and retail investors and national media active in the North American cannabis markets.

Since 2013, CFN Media has enabled the world's preeminent cannabis companies to thrive in the capital and public markets.

Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/featuredcompany

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on http://www.cannabisfn.com (the 'Site') is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

Frank Lane
206-369-7050
flane@cannabisfn.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/42549

Subscribe to the SCSD email list and get the latest small cap stock activity directly to your inbox, for free.

Part of the Stock Digest family of websites

Resource Stock Digest

MARKET SUMMARY

INDICES

Name Last Change
DOW 26656.40 0.55%
S&P 500 2933.68 0.88%
NASDAQ 8120.82 1.30%
TSX 16669.40 0.55%
TSX-V 608.48 0.00%
RTY 1585.09 1.58%

Technology

Name Last Change
APPL 207.48 1.42%
GOOG 1264.55 1.24%

@SmallCapDigest ON TWITTER